The "Preclinical Modelling" research group headed by Dr. Marc Zuckermann is also based at the KiTZ and focuses on the development and use of in vivo tumor models for high-grade gliomas in children.
We use state-of-the-art methods such as somatic gene delivery, in particular in utero electroporation, to induce targeted genetic changes directly in the brain. This allows us to rapidly test different combinations of genetic alterations identified in patient samples. The resulting tumors are transferred into allogeneic transplants, resulting in immunocompetent tumor models.
These models, supplemented by PDX models from collaborations, enable detailed biological investigations and the development of new therapeutic approaches. Our focus is on innovative treatments, including combination therapies and experimental gene therapies based on adeno-associated viruses (AAV). The aim is to find new ways to treat high-grade gliomas more effectively.
